Key result
Dabigatran reduces stroke and systemic embolism versus warfarin with similar major bleeding rates.
Why the study?
Does dabigatran reduce stroke and systemic embolism in patients with atrial fibrillation compared to warfarin?
Does dabigatran reduce stroke and systemic embolism in patients with atrial fibrillation compared to warfarin?
Dabigatran offers a dose-dependent alternative to warfarin in atrial fibrillation, with the 150 mg dose improving efficacy without increasing major bleeding, and the 110 mg dose reducing bleeding with similar efficacy.
Answers are grounded in this paper and cite their sources.
May support dabigatran 150 mg as warfarin alternative in AF; leaves open confirmation in larger trials.
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)
No takes yet. Share an insight, caveat, or question.
Connolly et al. (2009) studied this question. Dabigatran reduced stroke and systemic embolism rates compared to warfarin, while major hemorrhage rates remained similar.
Synapse has enriched 10 related papers. Consider them for comparative context: